NCT00445432 - A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2010

Conditions

Crohn's Disease

Interventions

BIOLOGICAL

adalimumab

Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)

OTHER

Placebo

Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)

Trial Locations (29)

Unknown

Site Ref # / Investigator 46965, Aichi

Site Ref # / Investigator 46977, Aichi

Site Ref # / Investigator 46978, Aichi

Site Ref # / Investigator 46979, Aichi

Site Ref # / Investigator 46922, Chiba

Site Ref # / Investigator 46974, Chiba

Site Ref # / Investigator 46970, Ehime

Site Ref # / Investigator 46971, Fukuoka

Site Ref # / Investigator 46985, Fukuoka

Site Ref # / Investigator 46986, Fukuoka

Site Ref # / Investigator 46987, Fukuoka

Site Ref # / Investigator 46968, Hiroshima

Site Ref # / Investigator 46973, Hokkaido

Site Ref # / Investigator 6881, Hokkaido

Site Ref # / Investigator 46982, Hyōgo

Site Ref # / Investigator 46969, Kagawa

Site Ref # / Investigator 46927, Kanagawa

Site Ref # / Investigator 46984, Kochi

Site Ref # / Investigator 46981, Kyoto

Site Ref # / Investigator 46921, Miyagi

Site Ref # / Investigator 46983, Okayama

Site Ref # / Investigator 46966, Osaka

Site Ref # / Investigator 46967, Osaka

Site Ref # / Investigator 46980, Shiga

Site Ref # / Investigator 46964, Shizuoka

Site Ref # / Investigator 46923, Tokyo

Site Ref # / Investigator 46924, Tokyo

Site Ref # / Investigator 46975, Tokyo

Site Ref # / Investigator 46976, Tokyo